Vimarsana
Biggest News Aggregation in the World

Wave Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Wave Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Wave Bio Today - Breaking & Trending Today

First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced - Vimarsana News

First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced

BOCA RATON, Fla., Dec. 27, 2023 -- First Wave BioPharma, Inc. , a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal ...

First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company - Vimarsana News

First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company

Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal disease clinical pipeline A concurrent institutional...

777% Gain Implied in Analyst's Target Price on Biopharma Co. - Vimarsana News

777% Gain Implied in Analyst's Target Price on Biopharma Co.

777% Gain Implied in Analyst's Target Price on Biopharma Co.

First Wave BioPharma, Inc. Announces Closing of $9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Vimarsana News

First Wave BioPharma, Inc. Announces Closing of $9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

BOCA RATON, Fla., March 02, 2022 -- First Wave BioPharma, Inc. , a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies... | March 2, 2022